BACKGROUND: End-stage renal disease patients experience significant impairments in health-related quality of life (HRQOL). Testing various strategies to improve patient HRQOL in multicenter clinical trials, such as the Frequent Hemodialysis Network (FHN) trials is vitally important. AIMS: The aim of this paper is to describe the design and conduct of HRQOL and patient-reported outcomes (PRO) assessment in the FHN trials. METHODS: In the FHN trials, HRQOL was examined as a multidimensional concept, and the SF-36 RAND Physical Health Composite score was one of the co-primary outcomes. The instruments completed to assess HRQOL included the Medical Outcomes Study Short Form SF-36, Health Utilities Index 3, Sleep Problems Index, Beck Depression Inventory and feeling thermometer. These instruments have been shown to have high reliability, validity and responsiveness to change in the end-stage renal disease population. Additional items evaluating PRO including sexual function, time to recovery after dialysis and patients' self-perceived burden to caregiver were also assessed. All questionnaires were administered by trained interviewers using computer-assisted telephone interviewing to ensure blinding and minimizing selection bias. Interim analysis reveals that these instruments can be used to collect a comprehensive set of HRQOL measures with minimal patient burden. CONCLUSIONS: Accurate measurement of HRQOL and PRO can help us test whether hemodialysis interventions improve the health and well-being of this compromised patient population. We have shown that a comprehensive set of HRQOL measures can be centrally collected through telephone interviews in a blinded fashion, in a way that is well tolerated with minimum respondent burden.
BACKGROUND: End-stage renal diseasepatients experience significant impairments in health-related quality of life (HRQOL). Testing various strategies to improve patient HRQOL in multicenter clinical trials, such as the Frequent Hemodialysis Network (FHN) trials is vitally important. AIMS: The aim of this paper is to describe the design and conduct of HRQOL and patient-reported outcomes (PRO) assessment in the FHN trials. METHODS: In the FHN trials, HRQOL was examined as a multidimensional concept, and the SF-36 RAND Physical Health Composite score was one of the co-primary outcomes. The instruments completed to assess HRQOL included the Medical Outcomes Study Short Form SF-36, Health Utilities Index 3, Sleep Problems Index, Beck Depression Inventory and feeling thermometer. These instruments have been shown to have high reliability, validity and responsiveness to change in the end-stage renal disease population. Additional items evaluating PRO including sexual function, time to recovery after dialysis and patients' self-perceived burden to caregiver were also assessed. All questionnaires were administered by trained interviewers using computer-assisted telephone interviewing to ensure blinding and minimizing selection bias. Interim analysis reveals that these instruments can be used to collect a comprehensive set of HRQOL measures with minimal patient burden. CONCLUSIONS: Accurate measurement of HRQOL and PRO can help us test whether hemodialysis interventions improve the health and well-being of this compromised patient population. We have shown that a comprehensive set of HRQOL measures can be centrally collected through telephone interviews in a blinded fashion, in a way that is well tolerated with minimum respondent burden.
Authors: P L Kimmel; R A Peterson; K L Weihs; S J Simmens; D H Boyle; I Cruz; W O Umana; S Alleyne; J H Veis Journal: J Am Soc Nephrol Date: 1995-11 Impact factor: 10.121
Authors: Amit X Garg; Rita S Suri; Paul Eggers; Fredric O Finkelstein; Tom Greene; Paul L Kimmel; Alan S Kliger; Brett Larive; Robert M Lindsay; Andreas Pierratos; Mark Unruh; Glenn M Chertow Journal: Kidney Int Date: 2017-01-13 Impact factor: 10.612
Authors: Manisha Jhamb; Kelly Liang; Jonathan Yabes; Jennifer L Steel; Mary Amanda Dew; Nirav Shah; Mark Unruh Journal: Am J Nephrol Date: 2013-12-10 Impact factor: 3.754
Authors: S Susan Hedayati; Divya M Daniel; Scott Cohen; Bryan Comstock; Daniel Cukor; Yaminette Diaz-Linhart; Laura M Dember; Amelia Dubovsky; Tom Greene; Nancy Grote; Patrick Heagerty; Wayne Katon; Paul L Kimmel; Nancy Kutner; Lori Linke; Davin Quinn; Tessa Rue; Madhukar H Trivedi; Mark Unruh; Steven Weisbord; Bessie A Young; Rajnish Mehrotra Journal: Contemp Clin Trials Date: 2015-11-24 Impact factor: 2.226
Authors: Katalin Z Ronai; Andras Szentkiralyi; Alpar S Lazar; Akos Ujszaszi; Csilla Turanyi; Ferenc Gombos; Istvan Mucsi; Robert Bodizs; Miklos Z Molnar; Marta Novak Journal: J Clin Sleep Med Date: 2017-04-15 Impact factor: 4.062
Authors: Ea Wha Kang; Francis Pike; Sarah Ramer; Khaled Abdel-Kader; Larissa Myaskovsky; Mary Amanda Dew; Mark Unruh Journal: Clin J Am Soc Nephrol Date: 2012-04-05 Impact factor: 8.237
Authors: Mark L Unruh; Brett Larive; Glenn M Chertow; Paul W Eggers; Amit X Garg; Jennifer Gassman; Maria Tarallo; Fredric O Finkelstein; Paul L Kimmel Journal: Am J Kidney Dis Date: 2013-01-15 Impact factor: 8.860
Authors: Maria-Eleni Roumelioti; Jennifer L Steel; Jonathan Yabes; Kevin E Vowles; Yoram Vodovotz; Scott Beach; Bruce Rollman; Steven D Weisbord; Mark L Unruh; Manisha Jhamb Journal: Contemp Clin Trials Date: 2018-09-09 Impact factor: 2.226